Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Bilastine Tablets in Healthy Subjects
NCT06098261Phase 1Unknown
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of bilastine in allergic rhinoconjunctivitis (ARC) and urticaria (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Peak Plasma Concentration at 48 hours, Area under the plasma concentration versus time curve from time 0 to time t at 48 hours and 1 more. Status: unknown.
02
Drugs
bilastine
03
Conditions
allergic rhinoconjunctivitis (ARC)urticaria
Beyond the preview
Go deeper on NCT06098261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06098261.